Defending Your Life: Sharer and Perlmutter On Amgen’s R&D Strategy
Since joining Amgen in 2000 and 2001, respectively, CEO Kevin Sharer and Exec VP-R&D Roger Perlmutter, have been the frontmen for the firm's aggressive approach to drug research and development - which has had some spectacular results. During the Aug. 15 call detailing the restructuring plan to analysts, the duo was asked about Amgen's ramp-up of R&D in 2006 and generally about R&D productivity. Their answers provide perspective on the feeling surrounding the need to cut back on the area where Amgen has taken such a lead in the industry, on the unique difficulties of being a biotech giant, and on Amgen's performance compared to its closest competitor - Genentech.
More from Archive
- • By
This is your final call to participate in the survey to better understand our subscribers’ content and delivery needs. The deadline is 20 September.
- • By
We are conducting a survey to better understand our subscribers’ content and delivery needs. If there are any changes you’d like to see in coverage topics, article format, or the method in which you access the Pink Sheet – or if you love it how it is – now is the time to have your voice heard.
More from Pink Sheet
- • By
It is unclear in a revised staff manual guide whether Commissioner's National Priority Voucher program approval “recommendations” from the drug and biologic center directors will be advisory or decisional, experts told the Pink Sheet.
- • By
Revised recommendation is based on most recent data on circulating strains in US, where KP.3 is now dominant. Novavax sticks with plans targeting the JN.1 ‘parent strain.’
- • By
Pink Sheet reporter and editors discuss the US FDA’s changes to the COVID-19 vaccine indication and its revocation of the vaccine emergency use authorizations, as well as new vaccine coverage and reimbursement questions.




